Sponsor: Representative Samuel Zager | Current Status: REFERRED to the Committee on HEALTH COVERAGE, INSURANCE AND FINANCIAL SERVICES

This bill requires insurance coverage, including coverage in the MaineCare program, for biomarker testing.

Sponsor: Representative Anne Graham | Current Status: REFERRED to the Committee on HEALTH AND HUMAN SERVICES

This bill requires the Department of Health and Human Services to provide reimbursement under the MaineCare program for glucagon-like peptide-1 receptor agonists that are approved by the federal Food and Drug Administration for the treatment of obesity. The department must restrict reimbursement to medications prescribed by a primary care provider or a bariatric specialist and must require a prior authorization of the medication.

Sponsor: Senator Stacy Brenner | Current Status: REFERRED to the Committee on HEALTH COVERAGE, INSURANCE AND FINANCIAL SERVICES

This bill requires carriers offering health plans in this State to provide coverage for blood testing for perfluoroalkyl and polyfluoroalkyl substances, or PFAS, recommended by a provider as medically necessary health care in accordance with clinical guidelines established by the National Academies of Sciences, Engineering, and Medicine. The requirements of the bill apply to health plans issued or renewed on or after January 1, 2026. The bill also includes language stating the Legislature's finding that the requirement for coverage for blood testing for perfluoroalkyl and polyfluoroalkyl substances are not an expansion of the State's essential health benefits and do not require the State to defray costs pursuant to the federal Patient Protection and Affordable Care Act.

Sponsor: Representative Laurie Osher | Current Status: REFERRED to the Committee on HEALTH AND HUMAN SERVICES

This bill requires carriers offering health plans in this State to provide coverage for glucagon-like peptide-1 receptor agonist medication approved by the federal Food and Drug Administration and prescribed by a health care provider. It also requires the Department of Professional and Financial Regulation, Bureau of Insurance to initiate an education campaign regarding the coverage requirements and the health benefits associated with the use of the medication. The requirements of the bill apply to health plans issued or renewed on or after January 1, 2026.